NNNN — Anbio Biotechnology Cashflow Statement
0.000.00%
Last trade - 00:00- $3.72bn
- $3.71bn
- $8.65m
Annual cashflow statement for Anbio Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2.54 | 10 | 2.25 | 2.37 | 6.4 |
| Non-Cash Items | 0 | -0.033 | -0.151 | -0.337 | 0.068 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.65 | -5.53 | -1.2 | 0.045 | -13.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 4.18 | 4.45 | 0.898 | 2.08 | -6.74 |
| Other Investing Cash Flow Items | 0 | -1.53 | 1.73 | 0.337 | -4.2 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -1.53 | 1.73 | 0.337 | -4.2 |
| Financing Cash Flow Items | — | 0 | -0.043 | -0.345 | -0.283 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | — | 0 | -0.043 | -0.345 | 6.95 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.18 | 2.92 | 2.59 | 2.07 | -3.99 |